Pathogen-Fed Insect Larvae for Antimicrobial Peptide Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for stimulating the expression of antimicrobial peptides (AMPs) in insect larvae using pathogens are not optimized, leading to suboptimal immune response in animals fed with unstimulated larvae.
Innovation Solution
Selectively altering the number and nature of pathogens, specifically using Pseudomonas syringae to stimulate Lucilia serricata larvae, results in a 30-fold increase in AMP expression, which is then fed to animals to enhance their immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If larvae are fed on food containing pathogens to stimulate AMP expression, then immune response is enhanced, but pathogenic risk and safety concerns increase
Solution Approach 1:
The patent converts the harmful effect of pathogens into a beneficial immune stimulant by using controlled exposure to specific bacterial species. The larvae are fed diets containing defined amounts of bacteria that stimulate AMP production without causing disease, thereby transforming a potentially harmful agent into a useful immunomodulator.
Solution Approach 2:
The patent optimizes multiple parameters including bacterial dose (10^6 to 10^9 CFU/g diet), larval age (4-7 days), and diet composition to achieve maximum AMP expression while maintaining safety. By precisely controlling these parameters, the system enhances immune response without allowing pathogenic effects to manifest.
2Reliability
If high doses of bacteria are used to stimulate AMP expression, then immune response is enhanced, but larval health and weight gain may be affected
Solution Approach 1:
The patent applies partial action by using sub-pathogenic doses of bacteria that are sufficient to stimulate immune response but insufficient to cause disease or significantly impact larval growth. The bacterial doses are carefully selected to provide immunostimulation without excessive burden on the larvae.
Solution Approach 2:
The patent systematically varies bacterial dose, larval age, and exposure duration to identify optimal parameters that maximize AMP expression while minimizing impact on larval weight gain. Experiments show that doses up to 10^9 CFU/g can stimulate immunity without preventing normal development when other nutritional needs are met.
3Reliability
If specific pathogenic bacteria are used to stimulate AMP expression, then targeted immune response is achieved, but safety and regulatory approval become more difficult
Solution Approach 1:
The patent selects bacterial species that are non-pathogenic or have very low pathogenicity to humans and animals, such as Pseudomonas syringae and Bacillus subtilis. These bacteria naturally occur in the environment and can be used to stimulate immune response without posing safety risks, thereby facilitating regulatory approval while maintaining targeted immune stimulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enhances the expression of AMPs in larvae, providing a significant reduction in Campylobacter colonization in the caecum of birds and stimulates host AMP expression, offering improved antibacterial activity in the intestine.
Implementation Method 1
Exposure of 4-day-old larvae to this bacterium for twelve hours has been found to increase AMP expression up to 30-fold as compared to unstimulated larvae
Data Source
AI summary
An improved method for the manufacture of a medicament, which method includes the use of tissues, larval forms or derivatives of insects that have been fed on food containing pathogens.